These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 29770165)

  • 1. Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.
    Davalli P; Marverti G; Lauriola A; D'Arca D
    Oxid Med Cell Longev; 2018; 2018():2389523. PubMed ID: 29770165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Basu B; Yap TA; Molife LR; de Bono JS
    Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redox modulation of the DNA damage response.
    Caputo F; Vegliante R; Ghibelli L
    Biochem Pharmacol; 2012 Nov; 84(10):1292-306. PubMed ID: 22846600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
    Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
    Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway.
    Chou WC; Hu LY; Hsiung CN; Shen CY
    Carcinogenesis; 2015 Aug; 36(8):832-40. PubMed ID: 26025911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.
    Jun DW; Hwang M; Kim YH; Kim KT; Kim S; Lee CH
    Oncotarget; 2016 Apr; 7(14):17699-710. PubMed ID: 26848527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DNA damage response: implications for tumor responses to radiation and chemotherapy.
    Goldstein M; Kastan MB
    Annu Rev Med; 2015; 66():129-43. PubMed ID: 25423595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics.
    Kinsella TJ
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S42-51. PubMed ID: 19393835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the DNA Damage Response in Cancer.
    O'Connor MJ
    Mol Cell; 2015 Nov; 60(4):547-60. PubMed ID: 26590714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breaking the DNA damage response to improve cervical cancer treatment.
    Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
    Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies.
    Li J; Lim JYS; Eu JQ; Chan AKMH; Goh BC; Wang L; Wong AL
    Antioxid Redox Signal; 2024 Aug; 41(4-6):322-341. PubMed ID: 38445392
    [No Abstract]   [Full Text] [Related]  

  • 13. DNA damage response regulation by microRNAs as a therapeutic target in cancer.
    Majidinia M; Yousefi B
    DNA Repair (Amst); 2016 Nov; 47():1-11. PubMed ID: 27697364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of DNA damage response and induction of apoptosis mediates synergism between doxorubicin and a new imidazopyridine derivative in breast and lung cancer cells.
    El-Awady RA; Semreen MH; Saber-Ayad MM; Cyprian F; Menon V; Al-Tel TH
    DNA Repair (Amst); 2016 Jan; 37():1-11. PubMed ID: 26590797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
    Arjumand W; Asiaf A; Ahmad ST
    Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy.
    Vecchio D; Frosina G
    Curr Drug Targets; 2016; 17(2):139-53. PubMed ID: 25382204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem?
    Sadoughi F; Mirsafaei L; Dana PM; Hallajzadeh J; Asemi Z; Mansournia MA; Montazer M; Hosseinpour M; Yousefi B
    DNA Repair (Amst); 2021 May; 101():103074. PubMed ID: 33640757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the microRNA-regulating DNA damage/repair pathways in cancer.
    Bottai G; Pasculli B; Calin GA; Santarpia L
    Expert Opin Biol Ther; 2014 Nov; 14(11):1667-83. PubMed ID: 25190496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of ataxia telangiectasia mutated kinase inhibitors.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
    Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
    Pan J; She M; Xu ZX; Sun L; Yeung SC
    Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.